An estimated 50 million people worldwide have epilepsy, 85% of whom reside in the low and low-middle income countries (LMICs). [1] In sub-Saharan Africa only 36% of children with epilepsy have access to antiseizure medications (ASMs) and 95% of this group are managed with phenobarbital. [2] One of the chronic side effects of ASMs are abnormalities in bone metabolism. [3,4]

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...